New data showed a survival advantage with newer chronic lymphocytic leukemia (CLL) treatments for older patients who are typically underrepresented in clinical trials.

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions ...

Follow the latest Artificial Intelligence news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to Artificial Intelligence notifications.